Endovia Health Sciences, Inc. (EDVA)
As-reported financials and SEC filings for Endovia Health Sciences, Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Endovia Health Sciences
- Revenue fell 90.9% to $73066 in FY2025, after a 95.7% decline the year before.
- Operating margin is -19415.6% in FY2025, -19158.6 pp against -257.0% in FY2021.
- Net loss widened to $25M in FY2025, from $24M in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Endovia Health Sciences’s fundamentals sit among the 113 Consumer Staples companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Endovia Health Sciences’s revenue growth of -90.9% is the lowest of the 110 Consumer Staples companies reporting it.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 14% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $73,066 | $801,273 | $18.9M | $18.1M | $11.3M |
| Gross profit | — | $-3.0M | $5.6M | $5.9M | $3.9M |
| Operating income | $-14.2M | $-9.9M | $-15.3M | $-21.4M | $-29.1M |
| Net income | $-25.2M | $-23.8M | $-21.0M | $-21.7M | $-29.1M |
| Diluted EPS | $-11.97 | $-17.68 | — | — | $-35.70 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $281,435 | $13,789 | $379,978 | $4.4M | $4.2M |
| Current assets | $631,993 | $1.9M | $4.0M | $10.7M | $8.3M |
| Total assets | $965,694 | $2.8M | $9.9M | $17.3M | $16.4M |
| Current liabilities | $16.3M | $19.4M | $14.8M | $5.0M | $6.5M |
| Long-term debt | $3,418 | $2.0M | $457,656 | $2.5M | $0 |
| Total liabilities | $16.3M | $21.4M | $15.5M | $8.0M | $7.5M |
| Total equity | $-15.3M | $-18.6M | $-5.6M | $9.3M | $8.9M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $-4.8M | $-7.3M | $-10.2M | $-14.0M | $-14.7M |
| Capital expenditure | — | $3,235 | $14,113 | $102,698 | $0 |
| Free cash flow | — | $-7.3M | $-10.2M | $-14.1M | $-14.7M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | — | — | $-2.1M | — |
| Q1 FY2026 | $4,224 | -93.8% | $-2.1M | $-0.47 |
| Q4 FY2025 | — | — | $-3.2M | $-1.15 |
| Q3 FY2025 | — | — | $-9.9M | — |
| Q2 FY2025 | — | — | $-8.5M | — |
| Q1 FY2025 | $68,606 | — | $-3.7M | $-1.97 |
| Q4 FY2024 | — | — | $-9.0M | — |
| Q3 FY2024 | — | — | $-4.7M | — |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest Consumer Staples peers
Monitor EDVA
Get an alert when Endovia Health Sciences files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor EDVA freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.